Completed PHASE2 INTERVENTIONAL NCT00307814

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

A Randomized, Open-Label Clinical Evaluation of PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease

Sponsor: Ortho Biotech Products, L.P.

Conditions Anemia Chronic Renal Insufficiency

Interventions Epoetin Alfa

Updated 5 times since 2017 Last updated: May 17, 2011 Started: Jan 31, 2002 Completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00307814, this PHASE2 trial focuses on Anemia and Chronic Renal Insufficiency and remains completed. Sponsored by Ortho Biotech Products, L.P., it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ortho Biotech Products, L.P.

Data source: Ortho Biotech Products, L.P.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.